Shu-Chi Tseng
Overview
Explore the profile of Shu-Chi Tseng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsiao C, Tseng S, Hsu C, Chiu L, Su L, Chan T
Front Immunol
. 2024 Nov;
15:1482000.
PMID: 39575249
Introduction: The clinical characteristics of patients positive for anti-small ubiquitin-like modifier 1-activating enzyme subunit 1 (SAE1) antibodies and diagnosed with idiopathic inflammatory myopathies (IIMs) vary across different cohorts and ethnicities,...
2.
Nishino M, Wang X, Ricciuti B, Tseng S, Park H, Alessi J, et al.
Eur Radiol
. 2023 Apr;
33(10):7284-7293.
PMID: 37099174
Objectives: The study investigated tumor burden dynamics on computed tomography (CT) scans in patients with advanced non-small-cell lung cancer (NSCLC) during first-line pembrolizumab plus chemotherapy, to provide imaging markers for...
3.
Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, et al.
Cancer Discov
. 2023 Apr;
13(7):1556-1571.
PMID: 37068173
Significance: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose...
4.
Tseng S, Gagne S, Hatabu H, Lin G, Sholl L, Nishino M
J Comput Assist Tomogr
. 2023 Mar;
47(4):590-597.
PMID: 36944140
Objective: This study aimed to investigate clinical and radiologic characteristics of lung cancer in lung transplant recipients and evaluate the treatment course and prognosis. Methods: The study included 448 patients...
5.
Nishino M, Wei Z, Mazzola E, Hino T, Tseng S, Sanchez M, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200603.
PMID: 36893377
Purpose: Patients with oncogene-driven advanced non-small-cell lung cancer (NSCLC) treated with effective targeted therapy demonstrate characteristic tumor volume dynamics with initial response, nadir, and subsequent regrowth. This study investigated tumor...
6.
Lamberti G, Aizer A, Ricciuti B, Alessi J, Pecci F, Tseng S, et al.
JCO Precis Oncol
. 2023 Feb;
7:e2200621.
PMID: 36809054
No abstract available.
7.
Tseng S, Lee H, Nishino M
Semin Respir Crit Care Med
. 2022 Oct;
43(6):887-898.
PMID: 36307109
Clinical applications of novel anticancer agents in the past few decades brought marked advances in cancer treatment, enabling remarkable efficacy and effectiveness; however, these novel agents are also associated with...
8.
Park H, Tseng S, Sholl L, Hatabu H, Awad M, Nishino M
Radiology
. 2022 Oct;
305(3):512-525.
PMID: 36283111
Small cell lung cancer (SCLC) is a highly aggressive malignancy with exceptionally poor prognosis, comprising approximately 15% of lung cancers. Emerging knowledge of the molecular and genomic landscape of SCLC...
9.
Chung W, Chen S, Ko T, Lin Y, Lin S, Lo Y, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077706
Triple-negative breast cancer (TNBC) is treated with neoadjuvant chemotherapy (NAC). The response to NAC, particularly the probability of a complete pathological response (pCR), guides the surgical approach and adjuvant therapy....
10.
Tseng S, Hino T, Hatabu H, Park H, Sanford N, Lin G, et al.
J Comput Assist Tomogr
. 2022 Aug;
46(6):871-877.
PMID: 35995596
Purpose: Interstitial lung abnormalities (ILAs) represent nondependent abnormalities on chest computed tomography (CT) indicating lung parenchymal damages due to inflammation and fibrosis. Interstitial lung abnormalities have been studied as a...